TORONTO, Sept. 26 /CNW/ - Predictive medicine company PreMD Inc.
(TSX: PMD; Amex: PME) today announced that the license, development and supply
agreements with McNeil Consumer Healthcare (McNeil) for PreMD's PREVU(*) Skin
Sterol Test will terminate in three months. As a result, PreMD will reacquire
all worldwide rights for the PREVU(*) family of skin sterol tests and will be in
a position to pursue other opportunities to commercialize the products. As
part of the termination provisions of the agreement, McNeil will be bound by
the terms of the agreement and will continue to support PREVU(*) for a period of
three months to ensure a smooth transition to PreMD.
